AstraZeneca’s Brilinta Gives Brilliant Sales Performance
This article was originally published in The Pink Sheet Daily
AstraZeneca’s cardiovascular drug Brilinta – one of the group’s five key growth platforms - seems to have turned the corner to give a stellar performance in the second quarter – particularly in the crucial US market.
You may also be interested in...
Who’s on first in China? That might be the a good question for AstraZeneca’s chief Pascal Soriot after the CEO of Pfizer also went out of his way to highlight second quarter success in the Middle Kingdom.
HHS Office of Inspector General’s Mary Riordan advises drug makers to analyze their speaker programs and consulting arrangements for possible kickback activities.
The company outlined plans to jumpstart growth of the anti-platelet drug Brilinta, including a 100% increase in marketing investment, increased rebates for payers and the addition of 200 nurse educators who will focus on the hospital discharge space.